UBS Group
CELG

UBS Group’s Celgene Corp CELG Stock Holding History

UBS Group’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,164,145
Closed -$215M – 8837
2019
Q3 		$215M Sell
2,164,145
-16,437
-0.8% -$1.56M 0.08% 233
2019
Q2 		$202M Sell
2,180,582
-2,629,135
-55% -$250M 0.08% 239
2019
Q1 		$454M Buy
4,809,717
+2,514,971
+110% +$220M 0.19% 128
2018
Q4 		$147M Sell
2,294,746
-1,365,558
-37% -$101M 0.07% 271
2018
Q3 		$328M Buy
3,660,304
+138,501
+4% +$12.2M 0.13% 173
2018
Q2 		$280M Sell
3,521,803
-422,085
-11% -$35M 0.12% 188
2018
Q1 		$352M Sell
3,943,888
-336,304
-8% -$32.3M 0.15% 155
2017
Q4 		$447M Buy
4,280,192
+1,087,228
+34% +$123M 0.18% 133
2017
Q3 		$466M Sell
3,192,964
-572,274
-15% -$77.9M 0.22% 109
2017
Q2 		$489M Buy
3,765,238
+386,159
+11% +$47.3M 0.25% 95
2017
Q1 		$420M Buy
3,379,079
+498,927
+17% +$59.7M 0.23% 98
2016
Q4 		$333M Buy
2,880,152
+33,384
+1% +$3.72M 0.18% 128
2016
Q3 		$298M Buy
2,846,768
+3,491
+0.1% +$378K 0.18% 132
2016
Q2 		$280M Buy
2,843,277
+149,151
+6% +$15.4M 0.18% 135
2016
Q1 		$270M Sell
2,694,126
-561,384
-17% -$57.8M 0.18% 128
2015
Q4 		$390M Buy
3,255,510
+426,328
+15% +$49.3M 0.25% 80
2015
Q3 		$306M Sell
2,829,182
-327,094
-10% -$40.6M 0.22% 96
2015
Q2 		$365M Sell
3,156,276
-154,714
-5% -$17.7M 0.24% 84
2015
Q1 		$382M Sell
3,310,990
-402,734
-11% -$48.1M 0.26% 77
2014
Q4 		$415M Buy
+3,713,724
New +$392M 0.29% 66

Other funds holding CELG

FP
Factorial Partners Mt. Kisco, New York $138M AUM 25.59% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $8.4B AUM 51.89% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

UBS Group's CELG Position: Q4 2019 in Review

UBS Group sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 2,164,145 shares — an estimated $215M sold.

UBS Group first reported a position in CELG in Q4 2014 and held it in 20 quarters. The position peaked at $489M in Q2 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • UBS Group reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • UBS Group sold 2,164,145 Celgene Corp shares in Q4 2019, an estimated $215M.
  • UBS Group first reported a position in Celgene Corp in Q4 2014 and held it in 20 quarters.
  • UBS Group's Celgene Corp position peaked at $489M in Q2 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.